Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07627698 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma

Name: Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma — clinical trial record (NCT07627698)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: DUET-MEL

StatusRecruiting

PhasePhase 1/2

SponsorBeijing Biotech

Started2026-03-02

View on ClinicalTrials.gov ↗

Beijing Biotech

32 trials monitored

See all monitored trials

Melanoma

1,020 trials monitored

See 45 trials at risk

This is a first-in-human, open-label, multicenter phase 1/2 study evaluating the safety, feasibility, recommended phase 2 dose (RP2D), and preliminary antitumor activity of allogeneic dual-target CSPG4/GD2 CAR-NK cells (EBDTKN-401) after lymphodepleting chemotherapy in adults with unresectable or metastatic cutaneous melanoma or metastatic uveal melanoma whose disease has progressed after standard therapy

Trial Details

NCT Number	NCT07627698
Lead Sponsor	Beijing Biotech
Conditions	Unresectable Melanoma, Metastatic Cutaneous Melanoma, Metastatic Uveal Melanoma
Enrollment	36 participants
Start Date	2026-03-02
Primary Completion	2027-06-14 (estimated)
Study Completion	2028-06-17 (estimated)
Updated on ClinicalTrials.gov	2026-06-04